Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD

Takahiro Nakajima, Hidetoshi Nakamura, Caroline A. Owen, Shuichi Yoshida, Keishi Tsuduki, Shotaro Chubachi, Toru Shirahata, Shuko Mashimo, Miho Nakamura, Saeko Takahashi, Naoto Minematsu, Hiroki Tateno, Seitaro Fujishima, Koichiro Asano, Bartolome R. Celli, Tomoko Betsuyaku

Research output: Contribution to journalArticlepeer-review

29 Citations (Scopus)


Purpose. This study aimed to examine whether plasma levels of cathepsin S or its inhibitor, cystatin C, may serve as biomarkers for COPD. Patients and Methods. We measured anthropometrics and performed pulmonary function tests and chest CT scans on 94 patients with COPD and 31 subjects with productive cough but no airflow obstruction ("at risk"; AR). In these subjects and in 52 healthy nonsmokers (NS) and 66 healthy smokers (HS) we measured plasma concentrations of cathepsin S and cystatin C using an ELISA. Data were analyzed using simple and logistic regression and receiver operating characteristic analyses. Results. Cathepsin S and cystatin C plasma levels were significantly higher in the COPD and AR groups than in the NS and HS groups (p<0.01). Among the COPD patients and AR subjects, plasma cathepsin S levels and cathepsin S/cystatin C ratios, but not cystatin C levels, were negatively related to severe airflow limitation (% FEV1 predicted < 50%; p=0.005) and severe emphysema as assessed by low attenuation area (LAA) score on chest CT scans (LAA ≥ 8.0; p=0.001). Conclusion. Plasma cathepsin S and cathepsin S/cystatin C ratios may serve as potential biomarkers for COPD.

Original languageEnglish
Article number4093870
JournalDisease Markers
Publication statusPublished - 2016

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Clinical Biochemistry
  • Biochemistry, medical


Dive into the research topics of 'Plasma Cathepsin S and Cathepsin S/Cystatin C Ratios Are Potential Biomarkers for COPD'. Together they form a unique fingerprint.

Cite this